Date & Time
October 12, 12:00 PM ET / 9:00 AM PT
About the Event
Allegro Ophthalmics has developed RSG, a synthetic peptide that targets inflammation and stress in the eye to treat Dry AMD and Dry Eye Disease, serious conditions that affect more than 30 million people in the U.S. alone.
- In Phase 2a clinical tests, Dry AMD a plurality patients taking RSG showed significant improvement in visual acuity.
- Dry Eye Disease patients are seeing similar results including a decrease in eye dryness score by more than 70 points.
Join our webinar with Vicken Karageozian, MD, CEO and President of Allegro Ophthalmics, to hear more about this amazing breakthrough and the path toward FDA approval for RSG.